Early access
Sign in
Taking people in United StatesPhase 2

Adding venous ethanol to catheter ablation for ventricular tachycardia after heart damage

Compares ablation alone with ablation plus venous ethanol in ischemic ventricular tachycardia.

Key facts

Who runs it
The Methodist Hospital Research Institute
Where
Houston, United StatesSee the site
Trial code
Registry title
Venous Ethanol for Ventricular Tachycardia
Status
Recruiting
Phase
Phase 2
People taking part
156 people, planned
Started
12 Apr 2023
Expected to end
12 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Venous ethanol
  • Catheter ablation
Record updated
24 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with ventricular tachycardia (a fast, dangerous heart rhythm) caused by damage from a past heart attack. All must already have an ICD (implanted defibrillator) and be able to have catheter ablation.

Age
18 to 85 years
Sex
Male and female
Disease stage
Ischemic cardiomyopathy after a prior heart attack. In the last 6 months: ≥3 VT episodes treated with pacing or drugs, ≥1 appropriate ICD shocks, ≥3 VT episodes within 24 hr, or sustained VT below the ICD detection rate.
Earlier treatment
Must already have an ICD implant.

Main reasons for not taking part

  • Creatinine clearance <25 cc/min, unless on dialysis
  • Left ventricular ejection fraction ≤10% or NYHA class IV heart failure
  • Mobile clot in the left ventricle, or severe aortic stenosis or mitral regurgitation with a flail leaflet
  • Heart surgery (unless VT was nonstop) or acute coronary syndrome in the past 2 months
  • Pregnancy, or expected survival under 12 months

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Male and female, ages of 18 and 85 years and with a prior ICD implant
  • Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause)
  • One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG/cardiac monitor
  • Patients deemed candidates for RF ablation of VT
  • Able and willing to comply with pre-, post-, and follow-up requirements
  • Willing to sign the informed consent

Who cannot take part

  • Disease process likely to limit survival to <12 months
  • New York Heart Association class IV heart failure
  • Cardiac surgery within the past 2 months (unless VT was incessant),
  • Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG)
  • Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia)
  • Covid-19 positive testing within 14 days of randomization procedure
  • Creatinine clearance <25 cc/min (using Cockcroft-Gault equation) except for patients on dialysis. (Contrast induced nephropathy is irrelevant in end-stage renal disease patients on dialysis, in whom the concern for contrast-induced renal dysfunction is not there since there is no chance of further kidney damage). Additionally, patients on dialysis will be excluded from the imaging sub-study
  • Left ventricular (LV) ejection fraction ≤10%
  • Mobile LV thrombus on echocardiography
  • Absence of vascular access to the LV
  • Severe aortic stenosis or mitral regurgitation with a flail leaflet
  • Pregnancy
  • Unwilling or unable to provide informed consent
  • Enrolled, or planning to get enrolled, in another research study during his/her participation on the Velvet trial

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

  • Houston Methodist HospitalHouston, United StatesContact: Chinwe Ngumezi, RNTaking people

About the trial

What the trial wants to find out

Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial

The 2 groups in the trial

  • ControlExisting treatment, for comparison

    Endocardial radiofrequency ablation of ventricular tachycardia

    Treatment: Catheter ablation

  • Venous ethanolTreatment being tested

    Endocardial radiofrequency ablation of ventricular tachycardia combined with venous ethanol ablation of the tachycardia substrate

    Treatment: Venous ethanol and Catheter ablation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Venous Ethanol for Ischemic Left Ventricular Tachycardia
Plain-language title
Adding venous ethanol to catheter ablation for ventricular tachycardia after heart damageGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05511246, who can take part
Record updated
24 July 2026